This year’s flagship industry event MedTech Forum was held over two days in Dublin, Ireland and broke all previous attendance records, welcoming over 1,000 participants across 49 sessions with 149 speakers – seven of which were from J&J.
JJMT shared the voices of business leaders and experts to shape discussion on the most critical topics in MedTech: from improving access to innovative products and services, advancing the digital agenda for better patient outcomes, to refining and transforming the regulatory framework for MedTech in Europe.
“It has been an honour to present at the #MTF2023! I had the unique opportunity to connect and discuss how data sharing transforms healthcare systems and the importance of European Health Data Space for patients’ lives”, said Marjolijn Klaver, EMEA VP Strategy and Market Development. During her speech, Marjolijn highlighted that, to deliver on the EHDS promise, the legislative framework should provide cost-effective access to data sets, as data is most powerful and provides insights when maximum connections are done.
Furthermore, the importance of data management and transparency within the MedTech sector was spotlighted during the session on EUDAMED, which will become fully functional in 2024. This session was moderated by Kevin Taylor, Associate Director, Regulatory Affairs Digital Capabilities EMEA.
Rocco De Bernardis, Global President Ottava & Advanced Visualization spoke on the panel A New Era in Robotic-Assisted Surgery: Present and Future, presenting Johnson & Johnson’s vision for the robotic assisted surgery (RAS). Rocco restated company’s commitment to a digital surgery ecosystem that goes beyond robotic-assisted systems, to reimagine the entire care pathway. He advocated for a multistakeholder dialogue on dedicated pathways for innovative products, as well as for global regulatory reliance to ensure robotics and digital solutions reach patients and healthcare systems as fast as possible.
The global Impact of EU MDR/IVDR was discussed at the panel featuring Peter Schroeer, VP Regulatory Affairs EMEAC, who signalled that the lack of predictability of the EU Medical Devices Regulation (MDR) and how this potentially translates into decreasing credibility and reputation for the EU, as a global regulatory benchmark.
Additionally, Christian Muelhendyck, Head of HEMA DACH, presented the preliminary insights from the J&J-led Innovative Health Initiative (IHI) project, focusing on the heterogenous use of data and evidence in regulatory and HTA decision-making. Furthermore, Gary Hartnett, VP of Partnership and External Supply LM, Janssen, shared his perspective on supply chain strategies that help to navigate the current challenges of the global manufacturing; and finally, Simon Neill, Senior Legal Director EMEA, joined a panel to discuss developments in liability legislation.
The JJMT physical booth at the Forum welcomed many colleagues and peers, and shared insights into our cutting-edge medical technologies and how they enhance patient outcomes.
To learn more about the MedTech Forum click here